Recent developments in hantavirus vaccine research underscore why traders assign only a 4.5% implied probability to approval or availability by the end of 2026. Multiple mRNA and DNA candidates, including those from Moderna-Korea University collaborations and UTMB’s single-dose Andes virus platform, remain in preclinical or early Phase I stages, with animal data showing protection but no completed human efficacy trials. Official sources confirm no FDA- or EMA-approved vaccines exist for New World strains causing hantavirus pulmonary syndrome, while existing Hantavax use is limited to Asia and certain Old World viruses. Outbreaks like the 2026 MV Hondius cluster have heightened surveillance but have not accelerated candidates past regulatory thresholds. Key upcoming milestones include further Phase I immunogenicity readouts and potential Phase II starts, though standard development timelines and the absence of Phase III data make licensure this year highly improbable absent unprecedented emergency authorization.